MBS 2320

Drug Profile

MBS 2320

Alternative Names: MBS-2320

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator University of Aberdeen
  • Developer Modern Biosciences
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2017 Modern Biosciences completes a phase I trial in Rheumatoid arthritis (Adjunctive treatment) in United Kingdom (NCT02480946)
  • 01 Jul 2015 Phase-I clinical trials in Rheumatoid arthritis (Adjunctive treatment) in United Kingdom (PO, Capsule) (NCT02480946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top